Aravis

Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.

Miikana Therapeutics is a private held biotechnology company. It is a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of cancer.

Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).

Miikana Therapeutics is a private held biotechnology company. It is a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of cancer.

MerLion Pharmaceuticals GmbH a pharmaceutical company, develops antibacterial drugs and biological products. The company offers finafloxacin, a fluoroquinolone antibiotic for the treatment of infection. The company was founded in 2008 and is based in Berlin, Germany. As of August 21, 2006, MerLion Pharmaceuticals GmbH operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

S*BIO Pte, Ltd., a biotech company, focuses on the discovery and clinical development of novel targeted small drugs for the treatment of cancer. It serves the biotechnology industry in Singapore. The company was founded in 2000 and is based in Singapore, Singapore. S*BIO Pte, Ltd. operates as a subsidiary of Chiron Corporation Limited.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Nura, Inc. purpose of discovering and developing pharmaceuticals for the treatment of neurodegenerative diseases, such as Parkinson’s and Alzheimers’s diseases, and behavioral disorders, such as depression, anxiety, schizophrenia, obesity and addiction.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

MerLion Pharmaceuticals GmbH a pharmaceutical company, develops antibacterial drugs and biological products. The company offers finafloxacin, a fluoroquinolone antibiotic for the treatment of infection. The company was founded in 2008 and is based in Berlin, Germany. As of August 21, 2006, MerLion Pharmaceuticals GmbH operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Borean Pharma ApS operates as a drug discovery and development company. The company's technology platform enables to design, develop, and produce pharmaceutical protein products. The company focuses on recombinant protein technology, as well as on antibody biopharmaceuticals. It offers protein products, antibody analogues, and CTLD library, as well as TNF antagonist for rheumatoid arthritis. The company was founded in 1997 and is based in Aarhus, Denmark.

ImVisioN Therapeutics is pioneering ILIT, a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more effective means of delivering allergy therapeutics. By applying another technology called modular antigen transporter (MAT), ImVisioN leverages the potential of ILIT to develop drugs that use allergens safely for specific and highly effective antigen presentation. In addition to the company’s lead product for the treatment of cat dander allergy, it also has programs addressing birch pollen and house dust mite allergies.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Athelas develops an in-home blood diagnostic device designed to monitor the immune system from a drop of blood. Its in-home blood diagnostic device is a portable optical unit for sample imaging and also analyzes blood cells and generates diagnostic reports helping doctors to identify leukemia, infections, and inflammatory diseases early, enabling patients to keep a check on their immunity level from home. The company was founded in 2016 and is headquartered in Mountain View, California.

Ikaria develop and deliver innovative therapeutics and interventions to meet the significant needs of critically ill patients. It is our aim to be an indispensable partner to clinicians, providing help and critically caring just when patients need it the most.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Synaffix BV is a biotechnology company that develops antibody-drug conjugate (ADC) technology platforms for oncology. It offers GlycoConnect, a site-specific antibody conjugation technology that modifies naturally-occurring glycan anchor points that exist on various antibodies to facilitate site-specific and stable conjugation of potent anti-cancer molecules. The company also offers HydraSpace, a payload-enhancing linker technology that is used to reduce ADC aggregation potential, increase payload solubility, improve conjugation efficiency, and enable higher drug loading. In addition, it offers a metal-free click chemistry that is applicable across pharma, biotech, and academic groups. The company was founded in 2010 and is based in Oss, the Netherlands.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Kalypsys provides pathway-based drug discovery and development services. The company implements discovery programs across a broad number of therapeutic areas using its automated and integrated suite of discovery technologies in biology, chemistry and informatics.

Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.

Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.